Xofluza
FDA expands approval of Genentech’s Xofluza for post-exposure prevention of influenza
November 24, 2020Manufacturing and Production, Sales and Marketing FDA, Xofluza, influenza
Genentech has secured FDA approval for Xofluza (baloxavir marboxil) for the post-exposure prevention of influenza in patients at least 12 …
FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza
October 18, 2019Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma
Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …
Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial
September 2, 2019Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma
Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …
First novel, single-dose flu drug approved in US in almost 20 years
October 25, 2018Sales and Marketing FDA, Shionogi, Xofluza, flu, influenza, pharma
The FDA has announced that it has approved the first single-dose flu drug with a novel mechanism of action in …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
